BioMark Diagnostics Inc.BUX.CN
Key ratios
FCF / Sales
-1827.8%2026
2025
-711.2%2024
-604.7%
ROA
-45.6%TTM
2026
-43.1%2025
-60.6%2024
-117.3%
ROE
-149.9%TTM
2026
-142.6%2025
-340.7%
Revenue growth
-61.2%2026
2025
-5.5%2024
6.3%
Recent news
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Track BUX.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer